🏠 Home How to use e-mentor 🎁 Earn Gifts by Studying
📚 Study Hub
🤖 AI Study PlannerPAID 🔁 Recap Cards ⚔️ 1v1 Study Duels NEW 📋 Test Series 💎 Test Series PackagesTIERS 🎁 Invite FriendsFREE PLANNER 📖 Track Chapters
⚡ Focus & Tools
🎧 Virtual Focus Room LIVE ⏱ Pomodoro Timer 🏆 Leaderboard 🎁 Earn Gifts by Studying
🌐 Community & Info
✍️ Blog ❓ Frequently Asked Questions ℹ️ Read Me First
Login Join Free
📢 UPDATES
📅 25th All India Debate Competition 2026  |  🏆 Leaderboard resets weekly — Keep your streak alive!  |  💡 Join Discussion Board for exam doubt clearing  |  📅 25th All India Debate Competition 2026  |  🏆 Leaderboard resets weekly — Keep your streak alive!  |  💡 Join Discussion Board for exam doubt clearing  | 

Ch 10: LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS — V2: Practical Scenarios & Case Laws

CS Executive 📚 Capital Market & Securities Laws 📖 Ch.10 — LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS 📘 V2: Study Material & Test Yourself ⚡ Free Mode (Answers Locked)
⏱ Duration: 90 Mins 🎯 Total Marks: 50 Passed at: 20 Marks Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (December 2026 Attempt - Syllabus 2022)

Exhaustive ICSI CS Executive Test Series with 4-Tier Rubrics, Statutory Analysis, and Real-world Corporate Problem Scenarios.

Login to Enroll & Start Join Free

📑 Exam Questions

5 Questions • Total 50 Marks

Question 1: SEBI (LODR) Regulations 2015: Regulation 17 Board Composition, Independent Directors, Woman Director.

10 Marks
📌 Applicable provisions of SEBI (LODR) Regulations, 2015 including Regulation 17(1), 17(1A), 17(1B), and 17(1C) along with Section 15HB of the SEBI Act, 1992.
Sahyadri Pharma Limited, a listed entity, recently reconstituted its Board of Directors to consist of 10 directors: 2 Executive Directors, 2 Non-Executive Non-Independent Directors, 3 Non-Executive Independent Directors (including 1 Woman Independent Director), 1 Woman Non-Executive Non-Independent Director, and 2 Professional Non-Executive Directors who are also independent. Due to sudden resignations on October 15, 2023, the total strength dropped to 7 directors, leaving only 2 Independent Directors and failing the requirement for a chairperson who is a non-executive director. Furthermore, the company failed to fill the casual vacancy of the Independent Director within the mandated timeline. Examine the validity of the board composition under Regulation 17 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, analyze the penal consequences under Section 15HB of the SEBI Act, 1992, and provide a 4-Tier Legal Opinion outlining the compliance roadmap.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 2: Audit Committee composition and mandatory review under Regulation 18.

10 Marks
📌 Strict enforcement of Regulation 18(1)(b) two-thirds independent director threshold and mandatory quorum of two independent directors.
Sahyadri Pharma Limited, a listed entity, constituted its Audit Committee with three members: Mr. A (Executive Director), Ms. B (Non-Executive, Non-Independent Director), and Mr. C (Non-Executive, Independent Director and Chairperson). The Audit Committee reviewed the quarterly financial statements and related party transactions for Q3 FY 2023-24, where Mr. C dissented on a material related party transaction with a firm owned by Mr. A's relative, yet the transaction was pushed through. Furthermore, SEBI later issued a show-cause notice alleging non-compliance with Regulation 18 of SEBI (LODR) Regulations, 2015 regarding committee composition, quorum, and mandatory review scope, alongside potential violations under Section 15A of the SEBI Act, 1992 and the SEBI (Prohibition of Insider Trading) Regulations, 2015 due to delayed disclosures. As the Company Secretary and Legal Advisor, draft an exhaustive 4-Tier Legal Opinion addressing the composition validity, statutory violations, SAT/Supreme Court precedents, and a comprehensive Secretarial Action Plan.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 3: Related Party Transactions policy, approval thresholds, and material RPT under Regulation 23.

10 Marks
📌 SEBI (LODR) (Sixth Amendment) Regulations, 2021 and subsequent operational circulars on RPTs.
Sahyadri Pharma Ltd., a listed entity on NSE and BSE, proposes to enter into a high-value lease agreement and raw material supply contract with Kalinga Biotech Pvt. Ltd., an entity where the Managing Director of Sahyadri Pharma holds a 35% equity stake and his spouse is a non-executive director. The annual transaction value under the supply contract is projected at Rs. 1,200 Crores, whereas Sahyadri Pharma's annual consolidated turnover as per the last audited financial statements is Rs. 12,000 Crores. Further, the lease rental involves an annual outflow of Rs. 65 Crores, exceeding 10% of the annual consolidated turnover of the listed entity when aggregated with other transactions with the same related party. The Audit Committee of Sahyadri Pharma approved the transactions by a majority vote of non-interested independent directors, but three promoter-nominated directors participated and voted on the resolution. Minority institutional shareholders holding 12% of the voting share capital have served a legal notice alleging violation of Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Section 188 of the Companies Act, 2013, contending that: (i) The transaction is a 'Material Related Party Transaction' requiring prior approval of shareholders through an ordinary resolution where all related parties must abstain; (ii) The participation of promoter-nominated directors vitiates the Audit Committee approval; and (iii) Penal consequences under Section 15A and Section 15HB of the SEBI Act, 1992, apply for failure to make proper disclosures and obtain requisite approvals. As the Chief Senior Examiner and designated Secretarial Advisor, frame a comprehensive 4-Tier Legal Opinion addressing the validity of the transactions, compliance thresholds, voting protocols, and secretarial remedial actions.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 4: Comprehensive review of key exam provisions of LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS (Part 4)

10 Marks
📌 Incorporates SEBI ICDR pricing mandates, LODR financial result timelines, PIT trading window closures, and SEBI Act penal provisions.
Sahyadri Pharma Ltd., a listed entity on NSE and BSE, is embroiled in a major corporate governance and compliance crisis. On 14th March 2024, the company's Board of Directors approved a preferential allotment of 5,00,000 equity shares and 2,00,000 convertible warrants to 'Kalinga Lifesciences LLP', a promoter-group entity, at a price of INR 450 per share, which was lower than the floor price calculated under Chapter V of SEBI (ICDR) Regulations, 2018. Simultaneously, it was revealed that Dr. H.R. Mehta, an Independent Director of Sahyadri Pharma Ltd., had traded in 25,000 shares of the company through his HUF account during the trading window closure period between 1st January 2024 and 16th March 2024 (prior to the board meeting), while also serving on the Audit Committee that discussed the strategic alignment of Kalinga Lifesciences. Furthermore, Sahyadri Pharma failed to submit its quarterly financial results for the quarter ended 31st December 2023 within the stipulated 45-day window under Regulation 33 of SEBI (LODR) Regulations, 2015, resulting in a freezing of promoter demat accounts by stock exchanges. Kalinga Lifesciences argues that the pricing was based on a 'special valuation methodology' certified by a chartered accountant and that independent directors are exempt from Structured Digital Database (SDD) tracking if trades are pre-cleared. As a Senior Company Secretary and Legal Counsel, draft an exhaustive 4-Tier Legal Opinion addressing: (i) The validity of the preferential issue pricing under SEBI (ICDR) Regulations, 2018 and consequential breaches under SEBI (LODR) Regulations, 2015; (ii) The liability of Dr. H.R. Mehta under SEBI (Prohibition of Insider Trading) Regulations, 2015 along with relevant SAT/Supreme Court precedents; (iii) The computation of minimum public shareholding (MPS) restoration timelines and open offer triggers under SEBI (SAST) Regulations, 2011; and (iv) The penal consequences under Sections 15A, 15G, and 15HB of the SEBI Act, 1992, alongside a comprehensive Secretarial Action Plan.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 5: Comprehensive review of key exam provisions of LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS (Part 5)

10 Marks
📌 Incorporates SEBI LODR (Amendment) Regulations relating to material business transfer approvals (Reg 37A), SDD mandates under PIT, and SAST creeping acquisition thresholds.
Sahyadri Pharma Ltd., a listed entity, faces a complex corporate governance and disclosure dispute under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Act, 1992 and the Securities Contracts (Regulation) Act, 1956 (SCRA). The company recently executed a strategic business transfer of its active pharmaceutical ingredient (API) division to an unlisted foreign subsidiary without prior shareholder approval via postal ballot. Simultaneously, the Managing Director and Chief Financial Officer failed to maintain a tamper-proof Structured Digital Database (SDD) under the SEBI (Prohibition of Insider Trading) Regulations, 2015 during the advance stages of negotiation, leading to selective leaks of unpublished price sensitive information (UPSI) and significant stock price volatility. Furthermore, the promoter group breached the creeping acquisition limits under Regulation 3(1) and Regulation 3(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by acquiring an additional 6.5% voting rights within a financial year through off-market inter-se transfers without triggering an open offer, while also failing to meet the Minimum Public Shareholding (MPS) requirement of 25% under Rule 19(2)(b) and Rule 19A of the SCRR, 1957. As the designated Company Secretary and Senior Legal Consultant, formulate an exhaustive 4-Tier Legal Opinion addressing the compounding statutory defaults, penalties under Sections 15A, 15G, and 15HB of the SEBI Act, 1992, SAT and Supreme Court precedents, and a concrete Secretarial Action Plan.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)
Advertisement

Quick Pomodoro Timer

Select a focus duration to launch your session:

25m Standard 50m Deep Focus 15m Quick Sprint
🎧 Join Virtual Focus Room (with 40Hz Audio) →
🔔
Daily Study Reminders
Get notified 15m before your target study sessions.